KalVista Pharmaceuticals (KALV) Other Working Capital Changes (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 4 years of Other Working Capital Changes data on file, last reported at $493000.0 in Q3 2025.

• For the quarter ending Q3 2025, Other Working Capital Changes fell 303.96% year-over-year to -$1.6 million; the trailing twelve-month figure through Jul 2025 stood at -$1.6 million (down 614.78% YoY), and the FY2025 full-year result was $1.4 million, up 152.42% from the prior year.
• Other Working Capital Changes retreated to -$1.6 million in Q3 2025, from $1.3 million in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $5.6 million in Q2 2022 to a low of -$2.2 million in Q2 2023.
• A 5-year average of $264777.8 and a median of $452000.0 in 2021 frame the typical range for Other Working Capital Changes.
• Peak annual rise in Other Working Capital Changes reached 1914.7% in 2022, while the deepest fall reached 409.6% in 2022.
• Tracing KALV's Other Working Capital Changes over 5 years: stood at $1.8 million in 2021, then plunged by 195.6% to -$1.7 million in 2022, then retreated by 2.86% to -$1.8 million in 2023, then fell by 19.27% to -$2.1 million in 2024, then gained by 24.1% to -$1.6 million in 2025.
• Business Quant data shows KALV's Other Working Capital Changes at $493000.0 in Q3 2025, -$3.8 million in Q2 2020, and -$1.6 million in Q1 2020.